Back to Journals » Journal of Blood Medicine » Volume 1

Review

Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia

       

Authors Lima, Arellano M, Holloway, Shepard M, McMillan S, Khoury HJ

Published 10 September 2010 Volume 2010:1 Pages 221—225

DOI https://doi.org/10.2147/JBM.S7158

Review by Single anonymous peer review

Peer reviewer comments 4

Download Article [PDF] 


Lisa M Lima, Martha Arellano, Stacie Holloway, Marian Shepard, Stephanie McMillan, Hanna Jean Khoury
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA

Abstract: Dasatinib (DAS) is a well tolerated oral dual SRC inhibitor with remarkable activity against all phases of imatinib-resistant chronic myeloid leukemia (CML). This paper focuses on the activity of DAS in intractable CML, and reviews outcomes of patients enrolled on DAS clinical trials. Safety and tolerability as well as practical tips for management of side-effects, and drug interactions are included.

Keywords: dasatinib, resistant CML, outcomes

Creative Commons License © 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]